

Out. number: 194-00-22/22.04.2024

Sales revenues for March 2024

Sofia, Bulgaria, April 22, 2024 – According to the requirements of art. 100t of the Law on Public Offering of Securities (LPOS), “**Sopharma**” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies that for March 2024 the Company recorded a decrease in sales of 24% compared to the same month of the previous year, incl. 8% decrease in domestic sales and 32% decrease in export sales, mainly due to destabilizing market dynamics on the main export destinations.

From the beginning of 2024, the Company recorded a decrease in sales of 11%, incl. 1% decrease of domestic sales and 16% decrease in export sales.

Please, make the above information public in accordance with the provisions of art.100k, para 1 of the LPOS.

Pelagia Viatcheva

Investor Relations Director

Information about the company

Sopharma AD

Nearly 90 years of tradition and modernity - contemporary production, European standards and quality, best practices in the field of corporate and social responsibility.

Sopharma AD is the most successful Bulgarian company after the privatization, as from 2000 to today, the company realized 10 times growth in market capitalization and 25 times revenue growth. Over the past 10 years, Sopharma AD has been a leader in the pharmaceutical sector in Bulgaria.

Sopharma AD produces active substances and medicinal products; conducts activities related to development and implementation in the field of phytochemistry, chemistry and pharmacy, provides services related to production and other.

With 8 pharmaceutical plants in the country and the only ampoule factory in Bulgaria the company produces 3 billion tablets, 20 million syrup forms, has an authorization for over 200 generic products, 15 traditional products, 12 of which are plant-based, and uses more than 1500 tons of medicinal plants in its products.

Sopharma AD has an active and key role in raising the standard of living, in making people healthier, happier and protected. Sopharma AD is constantly investing in new technologies, innovations and research. The company maintains a dialogue with all players in the pharmaceutical industry and strives to contribute to improving the healthcare sector.

Sopharma Group

Sopharma Group is a vertically integrated healthcare business that operates in important health related sectors such as pharmaceuticals, hospital supplies, pharmaceutical products distribution and many others. “Sopharma” AD and its production subsidiaries have 8 pharmaceutical plants in Bulgaria, complying with the requirements of EU– GMP.